Clinical impact of in-stent late loss after drug-eluting coronary stent implantation

European Heart Journal

Volumn 28, Issue 13, 2007, Pages 1583-1591

  Moreno, Raúl ^a   Fernandez, Cristina ^b   Sanchez Recalde, Angel ^a   Galeote, Guillermo ^a   Calvo, Luis ^a   Alfonso, Fernando ^b   Hernandez, Rosana ^b   Sánchez Aquino, Rosa ^a   Angiolillo, Dominick J ^b   Villarreal, Sergio ^b   Macaya, Carlos ^b   Lopez Sendon, Jose L ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Drug eluting stents; Number of patients needed to treat; Restenosis

Indexed keywords

PACLITAXEL; TACROLIMUS;

ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; RESTENOSIS; SYSTEMATIC REVIEW;

CORONARY RESTENOSIS; DELAYED-ACTION PREPARATIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TACROLIMUS; TUBULIN MODULATORS;

EID: 34547809930     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl423     Document Type: Article

References (36)

1. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL Study Group. Randomized study with the Sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315- 1323.
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G, E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
5. Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ, C-SIRIUS Investigators. The Canadian Study of the Sirolimus-Eluting Stent in the Treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
6. Kelbaek H, Thuesen L, Helqvist S, Klovgaard L, Jorgensen E, Aljabbari S, Saunamaki K, Krusell LR, Jensen GV, Botker HE, Lassen JF, Andersen HR, Thayssen P, Galloe A, van Weert A, SCANDSTENT Investigators. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006;47:449-455.
7. Sabate M, Jimenez P, Angiolillo DJ, Gomez JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C, DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-2183.
8. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA, SES-SMART Investigators. Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-2734.
9. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent for acute myocardial infarction. A randomized trial. JAMA 2005;293:2109-2117.
10. Pache J, Dibra A, Mehilli J, Dirschinger J, Schömig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-1268.
11. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimuseluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;29:921-928.
12. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
13. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME, TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
14. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
15. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME, TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-1223.
16. Dawkins KD, Grube E, Guagliumi G Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME, TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial. Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-3313.
17. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE, for the ENDEAVOR-II Investigators. Randomized double-blind, multicenter study of the Endeavor zotarolimus-eluting stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006;114:798-806.
18. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Piedras C, Shimada Y, Sonoda S, Cristea E, Negrita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials). Am J Cardiol 2006;98:464-469.
19. Serruys PW, Ong ATL, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer everolimus-eluting stent with a bare-metal coronary stent: the SPIRIT first trial. Eurointervention 2005;1:58-65.
20. Morice MC, Bestehorn HP, Carrie D, Macaya C, Aengevaeren W, Wijns W, Bubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, Di Mario C. Direct stenting of de novo stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER-II trial. Eurointervention 2006;2:45-52.
21. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
22. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Stone GW. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1193-1200.
23. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.
24. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, REALITY Trial Investigators. Sirolimus- vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
25. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A, ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. A randomized controlled trial. JAMA 2005;293:165-171.
26. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A, ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
27. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A, for the Intracoronary drug-eluting stenting of Abrogate Restenosis in Small Arteries (ISAR-SMART 3) study investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-266.
28. de Lezo JS, Medina A, Pan M, Romero M, Delgado J, Segura J, Hernández E, Pavlovic D, Ojeda S, Fernandez J, Ariza J, Melian F. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 2005;45:75A.
29. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A, Intracoronary Stenting Angiographic Restenosis - Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-279.
30. Kandzari DE, Leon MB. ENDEAVOR-III. A randomized trial to confirm the safety and efficacy of the Medtronic zotarolimus eluting coronary stent in de novo native coronary artery lesions. Transcatheter Cardiovascular Interventions Sessions 2005 (http://www.tctmd.com/csportal/ShowBinary/BEA%20Repository/ TCTMD%20Portal/EPSlidePresPoolNew/2005/Oct2005Slides/Kandzari_TO5_M1100// pdfFile).
31. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
32. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111:3435-3442.
33. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005;45:308-311.
34. Moreno R, Fernandez C, Alfonso F, Hernandez R, Bañuelos C, Escaned J, Macaya C. Comparison between Cypher and Taxus stents. Results from a meta-analysis including five randomized trials. Circulation 2005; 112 (Abstr. Suppl.): 3067. Available at: http://www.abstractsonline. com/arch/RecordView.aspx?LookupKey=12345&recordID=19124.
35. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomized trials. JAMA 2005;294:819-825.
36. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-1573.